US Court Signs Off $70m Glenmark, Merck Settlement In Zetia ‘Pay-For-Delay’ Case
Indian Firm Announced Total Proposed Bill Of $87.5m Earlier This Year With Three Classes
Months after signing off on claims from two other sets of plaintiffs, a US district court in Virginia has approved a settlement agreement with a third class to put to bed antitrust claims that Glenmark and Merck & Co conspired illegally to delay generic competition to Merck’s Zetia blockbuster.
You may also be interested in...
India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.
Glenmark has reached into its wallet to resolve claims, without admitting fault or liability, that it conspired with Merck to delay unlawfully generic competition to the originator’s Zetia.
A five-year old case on the cusp of trial involving Glenmark, Merck and the originator’s Zetia has produced a settlement dealing defendants out of the claims – for one class of plaintiffs at least.